Author Affiliations
Abstract
1 Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan, Hubei 430074, P. R. China
2 MoE Key Laboratory for Biomedical Photonics, School of Engineering Sciences, Huazhong University of Science and Technology, Wuhan, Hubei 430074, P. R. China
The anti-amyloid-β (anti-Aβ) fibrils and soluble oligomers antibody aducanumab were approved to effectively slow down the progression of Alzheimer's disease (AD) at higher doses in 2019, reaffirming the therapeutic effects of targeting the core pathology of AD. A timely and accurate diagnosis in the prodromal or pre-dementia stage of AD is essential for patient recruitment, stratification, and monitoring of treatment effects. AD core biomarkers amyloid-β (Aβ1β42), total tau (t-tau), and phosphorylated tau (p-tau) have been clinically validated to reflect AD-type pathological changes through cerebrospinal fluid (CSF) measurement or positron-emission tomography (PET) and found to have high diagnostic performance for AD identification in the stage of mild cognitive impairment. The development of ultrasensitive immunoassay technology enables AD pathological proteins such as tau and neurofilament light (NFL) to be measured in blood samples. However, combined biomarker detection or targeting multiple biomarkers in immunoassays will increase detection sensitivity and specificity and improve diagnostic accuracy. This review summarizes and analyzes the performance of current detection methods for early diagnosis of AD, and provides a concept of detection method based on multiple biomarkers instead of a single target, which may become a potential tool for early diagnosis of AD in the future.
Alzheimer's disease cerebrospinal fluid blood biomarkers bispecific antibody diagnosis. 
Journal of Innovative Optical Health Sciences
2022, 15(1): 2230001
Author Affiliations
Abstract
Department of Biomedical Engineering, Nanjing University of Aeronautics and Astronautics, 29 Yudao Street, Nanjing 210016, P.R. China
Because the brain edema has a crucial impact on morbidity and mortality, it is important to develop a noninvasive method to monitor the process of the brain edema effectively. When the brain edema occurs, the optical properties of the brain will change. The goal of this study is to access the feasibility and reliability of using noninvasive near-infrared spectroscopy (NIRS) monitoring method to measure the brain edema. Specifically, three models, including the water content changes in the cerebrospinal fluid (CSF), gray matter and white matter, were explored. Moreover, these models were numerically simulated by the Monte Carlo studies. Then, the phantom experiments were performed to investigate the light intensity which was measured at different detecting radius on the tissue surface. The results indicated that the light intensity correlated well with the conditions of the brain edema and the detecting radius. Briefly, at the detecting radius of 3.0 cm and 4.0 cm, the light intensity has a high response to the change of tissue parameters and optical properties. Thus, it is possible to monitor the brain edema noninvasively by NIRS method and the light intensity is a reliable and simple parameter to assess the brain edema.
Cerebrospinal fluid gray matter white matter reduced scattering coe±cient light intensity 
Journal of Innovative Optical Health Sciences
2017, 10(3): 1650050

关于本站 Cookie 的使用提示

中国光学期刊网使用基于 cookie 的技术来更好地为您提供各项服务,点击此处了解我们的隐私策略。 如您需继续使用本网站,请您授权我们使用本地 cookie 来保存部分信息。
全站搜索
您最值得信赖的光电行业旗舰网络服务平台!